Tag Archives: Chuck Wilson

Reality Check: Cancer Experts Discuss Hurdles Facing CAR-T Therapy

There’s a lot of excitement these days about a type of cellular immunotherapy known as CAR-T, a method of modifying peoples’ immune cells to fight cancer. But you could also fill a book listing all the problems its makers will have to solve—how to test, manufacture, and even the define the nature of these cancer-killing […]

East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More

New startups. New data. Financings. Acquisitions. Legal tussles. FDA advisory panels. It’s been that kind of week in East Coast biotech. So grab some coffee and let’s roll through this week’s headlines. —This week a new type of cholesterol-lowering drug was in the spotlight, a class of injectable therapies that block the protein known as […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged Accelerate Long Island, Acute Myeloid Leukemia, Agios Pharmaceuticals, Alan Crane, alirocumab, Alnylam Pharmaceuticals, Amgen, Amicus Therapeutics, Ankit Mahadevia, Antibiotics, Beta-Thalassemia, Biotech, BlueBird Bio, Celgene, Chuck Wilson, Clarus Ventures, Codagenix, deals, Dicerna Pharmaceuticals, evolocumab, FDA, Gary Glick, Gene Therapy, Immunotherapy, Inflammatory Bowel Disease, IPO, Ironwood Pharmaceuticals, J. Robert Coleman, Life Sciences, Lundbeckfond Ventures, Lycera, Merck, Merck Research Ventures, New Enterprise Associates, PCSK9, Polaris Partners, post-partum depression, Praluent, pyruvate kinase deficiency, Regeneron Pharmaceuticals, Repatha, RNA Interference, Roundups, Sage Therapeutics, Sanofi, Scott Requadt, Seattle Genetics, Sirna Therapeutics, Spero Therapeutics, startups, Stroma, the Kraft Group, Topspin Partners, Unum Therapeutics, Vaccine, Xtuit Pharmaceuticals | Comments Off

IPO “On the Horizon” for Unum After $65M Series B, CEO Says

It’s been quite a week for Unum Therapeutics. Just three days after inking its first partnership, the emerging cellular immunotherapy startup has bagged its biggest funding round to date, and an initial public offering may not be far behind. Cambridge, MA-based Unum this morning raised a $65 million Series B round from a large group […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, Seattle blog main, Seattle top stories | Tagged Atlas Venture, Brace Pharma Capital, Chuck Wilson, Cowen Private Investments, deals, Fidelity Biosciences, IPO, Jennison Associates, Juno Therapeutics, Kite Pharma, Life Sciences, New Leaf Venture Partners, Novo A/S, Sabby Management, Sanofi-Genzyme Bioventures, Seattle Genetics, Sectoral Asset Management, startups, Unum Therapeutics, VC, Wellington Management | Comments Off

Seattle Genetics Pays $25M to Buy Into Unum’s Souped-Up T-Cell Therapy

Unum Therapeutics started up last year with its own twist on the increasingly crowded field of cellular immunotherapy. Today, that plan got a stamp of support from Seattle Genetics. SeaGen (NASDAQ: SGEN) has agreed to team up with Cambridge, MA-based Unum in a broad deal to use the former’s antibodies with Unum’s cellular immunotherapy technology […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, Seattle blog main, Seattle top stories | Tagged Adcetris, Antibody-Drug Conjugates (ADCs), Atlas Venture, Brentuximab Vedotin, CD19, Chuck Wilson, Clay Siegall, deals, Fidelity Biosciences, Juno Therapeutics, Kite Pharma, Life Sciences, Sanofi-Genzyme Bioventures, Seattle Genetics, startups, T-cell therapy, Unum Therapeutics, VC | Comments Off

Seven Takeaways From “What’s Hot in Boston Biotech”

Sure, things may look great now, but it wasn’t long ago that Kendall Square was a biotech ghost town—and the good times might come to an end if we’re not careful. Meanwhile, gene therapy, cell therapy, and microbiome research look poised to make an impact on healthcare—just don’t overlook the hurdles that remain, or underestimate […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories | Tagged Acute Lymphoblastic Leukemia, Adam Koppel, Alexis Borisy, American Laboratory Trading, Amir Nashat, Amyotrophic Lateral Sclerosis, Ben Auspitz, Bernat Olle, chimeric antigen receptor, Chuck Wilson, Cote Orphan, David Altshuler, events, Fairfax County Economic Development Authority, Fidelity Biosciences, Flagship Ventures, Gene Therapy, James Collins, Johnson & Johnson Innovation, Keith Spiro, KeithSpiroPhoto, Life Sciences, Marian Nakada, Michelle Dipp, Microbiome, Mintz Levin Cohn Ferris Glovsky and Popeo, Noubar Afeyan, Olivier Danos, OvaScience, Parkinson's, people, Peter Kolchinsky, Polaris Partners, Precision Medicine, President Obama, PureTech, RA Capital Management, Samantha Singer, Sample6, Steve Paul, Susan Lindquist, Synlogic, Synthetic Biology, The Broad Institute of MIT and Harvard, Tony Coles, Unum Therapeutics, Vedanta Biosciences, Vertex Pharmaceuticals, Voyager Therapeutics, What's Hot in Boston Biotech, Whitehead Institute, Yumanity Therapeutics | Comments Off

Find Out “What’s Hot in Boston Biotech” on April 8

Life sciences innovation is moving fast these days, and Boston is right in the center of it. Consider the past year alone: Gene therapy, once an abandoned research field fraught with safety issues, produced real human data suggesting it might be able to reverse a crippling blood disorder. Cellular immunotherapy techniques are showing real promise […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories | Tagged Adam Koppel, Amir Nashat, Biogen Idec, Cellular Immunotherapy, Chuck Wilson, events, Gene editing, gene sequencing, Gene Therapy, IPOs, Life Sciences, Michelle Dipp, Microbiome, Novartis, Olivier Danos, Onyx Pharmaceuticals, OvaScience, people, Precision Medicine, Samantha Singer, startups, Susan Lindquist, The Broad Institute of MIT and Harvard, Tony Coles, Unum Therapeutics, What's Hot in Boston Biotech, Whitehead Institute, Yumanity Therapeutics | Comments Off

Inside a Life Sciences Industry Confab: Notes from Convergence

It didn’t bother me that my attendee badge was missing from the registration booth when I arrived at Convergence: The Life Sciences Leaders Forum in Newport, RI, last week. I suspect it was stolen by the same conference gremlins who bilked my badge at the NVCA annual meeting this spring, the 2007 BIO meeting in […]

Posted in Boston, Boston blog main, National blog main | Tagged Achaogen, Acucela, Alan Eisenberg, Alnylam Pharmaceuticals, Biogen Idec, Biotechnology Industry Organization, Christoph Westphal, Chuck Wilson, Convergence, Drugs, Future Foward Events, Genzyme, GlaxoSmithKline, Henri Termeer, John Hollway, John Maraganore, JP Morgan Healthcare Conference, Life Sciences, Novartis, NVCA, Oxford Bioscience Partners, people, Ryo Kubota, sirtris, VC | 1 Comment

New Biotech Biz Models (and the Tested Bob Langer-Terry McGuire Approach) Emerge at Xconomy Forum

We could have called it the “New Biotech Business Model Expo.” Xconomy’s forum—How to Build a Life Sciences Company—attracted venture capitalists and entrepreneurs from around the Boston area (and a few from across the country) to the Novartis Institutes for Biomedical Research in Cambridge on Tuesday morning to showcase the strategies they’ve used to form […]

Posted in Boston, Boston blog main, National blog main | Tagged Accelerator Corp., Alex Rives, Amir Nashat, Biotech, Bob Langer, Carmichael Roberts, Chuck Wilson, David Schubert, David Steinberg, David Walt, Enlight Biosciences, events, Fate Therapeutics, Life Sciences, MIT, Myer Berlow, Nano-Terra, Nicholas Naclerio, North Bridge Venture Partners, Novartis, people, Polaris Venture Partners, PureTech Ventures, Quanterix, RXi Pharmaceuticals, Terry McGuire, Tod Woolf | Comments Off

Tag Archives: Chuck Wilson

Archives

Meta